AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03752619 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Non Contracting Producing Peripheral Nerve Stimulation
Description: The stimulation system includes an external stimulator, percutaneous lead and pad. The stimulator snaps onto the pad. The pad has an embedded power source but also serves as the anode. The 1-channel stimulator outputs a biphasic current waveform with current pulse parameter ranges suitable for Peripheral Nerve Stimulation (PNS). The percutaneous lead is inserted using an introducer (like a hypodermic needle) which is withdrawn and the lead is retained in the muscle by a barb at its tip. After a 1-week stabilization period, stimulation is initiated (6 hrs/day). The duty cycle and daily dose remain constant, but stimulus parameters may be adjusted by the research staff as deemed appropriate. The treatment period is 3 weeks after which the lead will be removed.
Study NCT03752619 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Therapy
Description: All participants receive eight 1.0 hr. sessions of physical therapy (PT) over a 4-wk period from a therapist blinded to Peripheral Nerve Stimulation (PNS) treatment assignment. Each participant also performs home exercises. The primary objective of physical therapy (PT) and the home exercise program is to prevent re-injury by educating and training participants in the biomechanics and proper use of the shoulder and upper limb. During each in-lab session, participants are trained in the implementation of these exercises, which are individually adjusted and progressed with increasing external loads by using weights and elastic rubber bands.
Study NCT03752619 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical Therapy
Description: All participants receive eight 1.0 hr. sessions of physical therapy (PT) over a 4-wk period from a therapist blinded to Peripheral Nerve Stimulation (PNS) treatment assignment. Each participant also performs home exercises. The primary objective of physical therapy (PT) and the home exercise program is to prevent re-injury by educating and training participants in the biomechanics and proper use of the shoulder and upper limb. During each in-lab session, participants are trained in the implementation of these exercises, which are individually adjusted and progressed with increasing external loads by using weights and elastic rubber bands.
Study NCT02290717 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fractional CO2 laser
Study NCT02290717 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NB-UVB therapy
Description: NB-UVB therapy (according to the standard treatment protocol of the SNIP, which the patient is already been treated with) will be continued for both treated and control sites during 6 months.
Study NCT02290717 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: NB-UVB therapy
Description: NB-UVB therapy (according to the standard treatment protocol of the SNIP, which the patient is already been treated with) will be continued for both treated and control sites during 6 months.
Study NCT02290717 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone Propionate Cream 0.05%
Description: 4 times a week (standard IPD protocol)
Study NCT04504318 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apixaban 2.5 MG Oral Tablet
Description: Patients will be assigned to the respective study groups postoperatively upon arrival in the post-anesthesia care unit. Hence, surgeons are blinded at the time of surgery as to study group assignment. Chemoprophylaxis will continue for the duration of the hospitalization.
Study NCT04504318 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enoxaparin 40Mg/0.4mL Prefilled Syringe
Description: Patients will be assigned to the respective study groups postoperatively upon arrival in the post-anesthesia care unit. Hence, surgeons are blinded at the time of surgery as to study group assignment. Chemoprophylaxis will continue for the duration of the hospitalization.
Study NCT00772005 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: armodafinil
Description: 250 mg/day armodafinil
Study NCT02897388 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: breast milk consume promotion
Description: (1)Team building: organize a multidisciplinary breast milk consume improvement team；(2) Staff education: one nurse to train in Canada for 1 month as lactation coordinator, lactation consultant from Canada to teach NICU staff for 1 month; (3) Send breastmilk teaching materials for parents to teach mothers about breast milk feeding;(4) allocate an area in the NICU as a breast pumping room with breastfeeding pumps and chairs to support mothers pumping milk and feeding their babies; (5)purchase 10 breast pumps from Medela and establish a loaner program for mothers; (6)provide lactation counseling \& promote consistent communication about the benefits of mothers' milk to encourage mothers to provide milk for their infants;(7)Coaching by lactation coordinator and nursing staff
Study NCT03878875 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Session One Test Battery
Description: Prior to noise exposure:~Test battery - High-frequency audiometry, Distortion Product Otoacoustic Emissions, Middle Ear Muscle Reflex, Speech-in-Noise test (Around 35 minutes with breaks if required)~* Extended Frequency Audiometry (\~ 8 min), 0.25-16 kHz: Participants will be asked to press the button when they hear a sound through the headphones in a soundproof booth.~* DPOAE (\~ 5 min), 0.5-10 kHz: A small tip will be placed in participants' ear and they will hear a sound. The tip measures a response from hair cells in the cochlea and they will not need to do anything.~* MEMR (\~ 8 min), 4 kHz: A small tip placed in both ears and again a sound heard, however, this sound will gradually get louder until an involuntary muscle reflex is noted.~* Speech-in-Noise Test (\~ 5 min): Participants asked to repeat back a list of words as best as they can.~* Tinnitus: Participants were also asked if they experience any tinnitus i.e. bilateral, lasting > 5 minutes. This was reported as Y/N.
Study NCT03878875 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Session Two Test Battery
Description: Exposure at single loud music event (Important that this is part of participants' normal recreational routine, and specifically require that attendance is not prompted by participation in this study): Participants to use sound level meter provided from the Audiology Department at Charing Cross Hospital or sound level meter applications to measure sound levels inside the loud event.~Morning after exposure: Repeat test battery from session one - Ideally as soon as event is over.
Study NCT03878875 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Session Three Test Battery
Description: 1 week later (recovery): Repeat test battery.
Study NCT04580537 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enstilar
Description: Daily application on affected fingers (nail plates, nail folds, and surrounding skin)
Study NCT04580537 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enstilar
Description: Daily application on affected fingers (nail plates, nail folds, and surrounding skin)
Study NCT04580537 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ablative fractional laser
Description: Pre-treatment of affected fingers (nail plates, nail folds)
Study NCT01562249 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: orofacial myofunctional treatment protocol
Description: Once a week for six weeks, the experimental group received a forty minutes session of orofacial myofunctional treatment. A home exercise program was prescribed during each session. The protocol implies in continuous and daily practices - participants were asked to perform exercises at least three times a day. After the first six weeks, the experimental group underwent four sessions for maintenance purposes (two sessions twice a month and two sessions once a month). The total treatment duration was of five months.
Study NCT01562249 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: counseling
Description: The instruction group underwent two supervised forty minutes therapy sessions along the six weeks following surgery. These sessions involved the perception of the stomatognathic system, especially in terms of adequate performance during mastication. Specific exercises were not given and patients were instructed to try to reproduce the adequate pattern of mastication at all meals (i.e. alternated bilateral, with lip closure; with coordination activity of the tongue and mandible).
Study NCT01562249 — intervention group
Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: Control Group
Description: As the sEMG test-retest is a critical issue, participants of CG were also tested in two distinct moments (testing occurred with 1 year interval) in order to verify possible changes in the sEMG measurements as a result of retesting.
Study NCT00265525 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CardioFit
Description: CardioFit is a 26-week tailored web-based physical activity coaching service for individuals with Coronary Artery Disease (CAD). It has been designed to help patients develop personalized exercise programs based on their medical history, personal goals and preferences. Access to Cardio-fit is through a secured website. The cardio-fit website contains physical activity advice and heart health educational information. Each patient is assigned an on-line coach, whose role is to assist in creating safe an effective physical activity program, and to answer any questions that patients may have throughout the program.
Study NCT04267588 — intervention group
Intervention type: OTHER
Intervention: Navio Mobile App
Description: Participants will use the Navio Mobile App to track participants' pain and pain treatment
Study NCT01805973 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Training
Description: Patients will participate in a supervised exercise training programme for 18 weeks. Patients will participate in a 50 minute exercise regime three times a week.
Study NCT01034241 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Control
Description: Diet consists of 15 En% dairy protein and low GI, 55 En% carbohydrates and 30 En% fat
Study NCT01034241 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High dairy protein
Description: Diet consists of 25 En% dairy protein and low GI, 55 En% carbohydrates and 30 En% fat
Study NCT01034241 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: vegetable protein
Description: Diet consists of 15 En% vegetable protein and low GI, 55 En% carbohydrates and 30 En% fat
Study NCT01034241 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High GI
Description: Diet consists of 15 En% dairy protein and high GI, 55 En% carbohydrates and 30 En% fat
Study NCT02310893 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Combined Contingency Management and Peer Navigation
Study NCT02310893 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Contingency Management
Study NCT02310893 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Peer Navigation
Study NCT04206137 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group A (PNF rhythmic initiation group )
Description: Lifting of arms and push the head back through the pattern of flexion -abduction-external rotation and neck in extension to the left in opposition of therapist hand resistance will be asked to do. At the end range of motion extensor muscles of back will start to contract.Then, reversing of that movement pattern to extension-adduction-internal rotation and neck flexion to right against the therapist resisting hands will be asked. this will be repeated on both sides
Study NCT04206137 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Group B (Swiss ball exercises)
Description: Supine position: A ball will be placed under patient neck, and will be asked to bend hip and knee up to 90°. 5 times, 10 seconds hold Supine position: With a ball below the pelvis, knees bent, the ball press will be done with pelvis. 5 times, for 10 seconds hold.~Crawling position: With a ball below one knee while keeping toes away from contact with the floor, the patient will balance first to stabilize the posture and slowly raise the other lower limb. This exercise will be performed in turn for the two lower limbs 10 times, with 10 seconds hold.~Prone position: the patient will place a ball in front of pelvis and will repeatedly raise and lowered the two lower limbs alternately. There will be 10 repetitions, with 5 sets, taking 15 seconds rest between each set.
Study NCT04505449 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Left heart catheterization
Description: Patients who underwent left heart catheterization
Study NCT01010958 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valproic Acid
Description: Subjects should initiate therapy at 10 to 15 mg/kg/day. The dosage should be increased by 5 to 10 mg/kg/week to achieve optimal clinical response. Optimal clinical response is achieved at daily doses below 60 mg/kg/day. If satisfactory clinical response has not been achieved, plasma levels should be measured to determine whether or not they are in the usually accepted therapeutic range (50 - 100 µg/mL).
Study NCT01018160 — intervention group
Intervention type: DRUG
Intervention: Rabeprazole Sodium
Description: 10mg - 20mg tablet once or twice daily for 12 weeks
Study NCT03559439 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD19 CAR T
Description: CD19 CAR T cells transduced with a lentiviral vector to express anti-CD19 scFv CD3z:CD28 administered by IV infusion. Subjects will receive 0.1-10 x 10\^6 transduced CAR T cells as a split dose over three days as follows:Day 1, 10% fraction, Day 2, 30% fraction, Day 3, 60% fraction.
Study NCT01448044 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-790052 (NS5A Replication Complex Inhibitor)
Study NCT03091075 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxandrolone
Description: Treatment group will receive Oxandrolone daily for 12 weeks postoperatively
Study NCT03091075 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo group will receive placebo for 12 weeks postoperative
Study NCT03564795 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: KeraStat Gel
Description: Wound dressing for partial thickness burns
Study NCT03564795 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Silver Sulfadiazine
Description: Wound dressing for partial thickness burns
Study NCT02470403 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LIK066
Description: LIK066 25 mg tablets
Study NCT02470403 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: LIK066
Description: LIK066 25 mg tablets
Study NCT02470403 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo tablets
Study NCT01903681 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Circadin 2 mg
Description: First arm lower dose
Study NCT01903681 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Circadin 10 mg
Description: Second arm higher dose
Study NCT03802435 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: two-sessions of ultrasound-guided PIT
Description: two-sessions of ultrasound-guided PIT with 10cc D5W (3 months interval)
Study NCT03802435 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: One-sessions of ultrasound-guided PIT
Description: One-session of ultrasound-guided PIT with 10cc D5W and 10cc normal saline separately (3 months interval)
Study NCT03802435 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo ultrasound-guided injection with nerve hydrodissection
Description: Two-sessions of ultrasound-guided PIT with nerve hydrodissection with 10cc normal saline (3 months interval).
Study NCT01933178 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Cirrus AS-OCT
Study NCT04294251 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWP450
Description: Botulinum toxin type A(DWP450) will be administered intramuscularly to the bilateral masseter muscles on Day 1.
Study NCT04294251 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo(Normal Saline) will be administered intramuscularly to the bilateral masseter muscles on Day 1.
Study NCT03559803 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Drug: Cisplatin injection Weekly cisplatin (40 mg/m²) will be administered during radiotherapy. At least 3 cycles of cisplatin should be performed according to the hematological and renal functions but not mandatory.~Combination Product: radiotherapy A total dose of 45Gy in 25 fractions to the PTV is considered standard but simultaneous integrated boost or two steps boost to specific volumes (positive lymph nodes for example) are accepted and left to the investigator's discretion).
Study NCT04093492 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Preemie Prep for Parents (P3) Outpatient Mobile Intervention
Description: The P3 mobile intervention sends participants text messages according to a schedule based on their gestational age. These text messages contain links to short videos uploaded to the P3 site, focusing on topics related to preterm labor and premature infants.
Study NCT04093492 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ACOG links
Description: Participants in the active control condition will receive links to patient education handouts about preterm birth provided by the American College of Obstetricians and Gynecologists.
Study NCT00257205 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dacarbazine
Description: decarbazine 1000 mg/m2 IV Q 21 days x 12
Study NCT00257205 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-675,206
Description: CP-675,206 15 mg/kg IV Q 90 days x 4
Study NCT00257205 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: temozolomide
Description: temozolomide 200 mg/m2 orally on Days 1-5 every 28 days x 12
Study NCT02278692 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin K
Description: Oral vitamin K
Study NCT02278692 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral placebo tablet
Study NCT01053130 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laparoscopic sleeve gastrectomy
Description: laparoscopic sleeve gastrectomy plus dietary and physical activity support
Study NCT01053130 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: weight management program
Description: 1200-1500 kcal renal diet, increased physical activity, with optional orlistat therapy at 120 mg tds for 12 months
Study NCT00087126 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: topotecan hydrochloride
Study NCT04764786 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EVOO+POLY
Description: a test meal seasoned with extra virgin olive oil rich in polyphenols
Study NCT04764786 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: OO-POLY
Description: a test meal seasoned with olive oil poor in polyphenols
Study NCT05260424 — intervention group
Intervention type: OTHER
Intervention: non-invasive ventilation
Description: Babies who will have or won't have non-invasive ventilation failure in the first 72 hoursof life, will be compared.
Study NCT01448044 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo matching BMS-790052
Study NCT01448044 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated-interferon alfa 2a
Study NCT01448044 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pegylated-interferon alfa 2a
Study NCT01448044 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Study NCT01448044 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ribavirin
Study NCT01799720 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Less oxidized oil and diet
Description: Analyze the effect of dietary supplements Omega-3 with different levels of oxidation in the lipid profile of women who consume these supplements. For this purpose we have designed a single-blind, parallel-groups, randomized controlled trial. Finally 52 women between 25 and 75 years old randomly were distributed into three groups. Participants from group 1 took 2 capsules/day of one of the less oxidized oil (containing 300 mg EPA + DHA) and diet, . Follow-up 30 days
Study NCT01799720 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: More oxidized oil and diet
Description: Analyze the effect of dietary supplements Omega-3 with different levels of oxidation in the lipid profile of women who consume these supplements. For this purpose we have designed a single-blind, parallel-groups, randomized controlled trial. Finally 52 women between 25 and 75 years old randomly were distributed into three groups. Participants from group 2 took 2 capsules/day of one of the more oxidized oil (containing 300 mg EPA + DHA) and diet . Follow-up 30 days
Study NCT01799720 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hypercholesterolemic diet
Description: Analyze the effect of dietary supplements Omega-3 with different levels of oxidation in the lipid profile of women who consume these supplements. For this purpose we have designed a single-blind, parallel-groups, randomized controlled trial. Finally 52 women between 25 and 75 years old randomly were distributed into three groups. Participants from group 3 only received the diet and no capsules. Follow-up 30 days
Study NCT01162941 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Steroid refractory ITP
Description: a platelet count less than 20X109/L despite of treatment with full dose of steroid (prednisolone 1mg/kg for at least 4 weeks)
Study NCT02210962 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: essential fatty acids
Description: Yellow capsules containing eicosapentaenoic acid, docosahexaenoic acid (active)